We are live on ! Find out more
NEO icon

NeoGenomics

15.55 USD
+0.26
1.7%
At close Updated Nov 19, 10:02 AM EST
1 day
1.7%
5 days
-5.76%
1 month
-5.3%
3 months
-6.66%
6 months
85.34%
Year to date
32.23%
1 year
51.26%
5 years
-61.15%
10 years
70.5%
 

About: NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Employees: 2,500

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 23.1%
Neutral 69.2%
Negative 7.7%
Neutral
Business Wire
13 days ago
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 38th Annual Healthcare Conference.
NeoGenomics to Participate in Upcoming Investor Conferences
Positive
MarketBeat
21 days ago
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
NeoGenomics NASDAQ: NEO reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing, or NGS, testing, while raising its full-year revenue and adjusted EBITDA guidance.
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
Positive
Zacks Investment Research
21 days ago
NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
Neutral
Business Wire
21 days ago
NeoGenomics Reports Third Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its third-quarter results for the period ended September 30, 2026.
NeoGenomics Reports Third Quarter 2026 Results
Neutral
Business Wire
1 month ago
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
Neutral
Business Wire
1 month ago
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
Neutral
Benzinga
1 month ago
What's Going On With NeoGenomics Stock Tuesday?
Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NASDAQ:NEO) on Monday announced an executive succession plan and preliminary third-quarter financial results for the period ended Sept. 30, 2026.
What's Going On With NeoGenomics Stock Tuesday?
Negative
Investors Business Daily
1 month ago
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their chief executives would soon step down.
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Neutral
Business Wire
1 month ago
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
Positive
MarketBeat
1 month ago
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
NeoGenomics NASDAQ: NEO executives outlined the company's strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease testing and workflow tools designed for physicians treating patients closer to home.
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
Price charts implemented using Lightweight Charts™